GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Short Interest

IRLAB Therapeutics AB (OSTO:IRLAB A) Short Interest


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of IRLAB Therapeutics AB's Short Interest

For the Biotechnology subindustry, IRLAB Therapeutics AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IRLAB Therapeutics AB's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Short Interest distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Short Interest falls into.


;
;

IRLAB Therapeutics AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Short Interest
Comparable Companies
OSTO:XBRANE OSTO:IVACC OSTO:ACE OSTO:ELIC OSTO:CANTA OSTO:LIPUM OSTO:GUARD OSTO:XINT OSTO:ONCO XSAT:CESSA VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
Website
https://www.irlab.se
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines